drugset
drugset / Trial / NCT05870839

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

NCT05870839 ↗

Phase 1 Completed 121 enrolled Vaccine Company, Inc.
Non-randomizedSequentialOpen-labelPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of ascending dose levels of VXCO-100 in healthy adults.

Timeline

Start
2023-05-11
Primary completion
2024-04-10
Completion
2024-04-10

Drugs

EvaluationDrugModalityDoseRoute
Subject VXCO-100 Vaccine — Intramuscular

Indications

COVID-19